Trials / Completed
CompletedNCT00480766
A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of Oral Alendronate Sodium Once Weekly for the Prevention and Treatment of Glucocorticoid-Induced Bone Loss
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 173 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A research study to see how safe and effective MK0217 is when taken weekly for the prevention and treatment of steroid induced bone loss.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0217/Duration of Treatment : 12 Months |
Timeline
- Start date
- 2001-07-01
- Primary completion
- 2003-08-01
- Completion
- 2003-08-01
- First posted
- 2007-05-31
- Last updated
- 2024-08-14
Source: ClinicalTrials.gov record NCT00480766. Inclusion in this directory is not an endorsement.